NASDAQ : CRMD
CorMedix Inc. — Key statistics
Healthcare · Biotechnology · United States
Last price 7.64 USD (Oct 29, 2026, 4:00 PM EDT) · Market cap 595.49M
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Key statistics
Valuation
| Measure | Value |
|---|
| Market Cap | 443.89M |
| Enterprise Value | 334.66M |
Dates
| Measure | Value |
|---|
| Earnings Date | Nov 16, 2026 |
| Ex-Dividend Date | n/a |
Shares
| Measure | Value |
|---|
| Current Share Class | 77.94M |
| Shares Outstanding | 77.94M |
| Shares Change (YoY) | +40.04% |
| Shares Change (QoQ) | -0.54% |
| Owned by Insiders (%) | 7.42% |
| Owned by Institutions (%) | 49.00% |
| Float | 65.89M |
Ratios
| Measure | Value |
|---|
| PE Ratio | 2.73 |
| Forward PE | n/a |
| PS Ratio | 0.96 |
| Forward PS | 1.80 |
| PB Ratio | 0.96 |
| P/TBV Ratio | 6.13 |
| P/FCF Ratio | 1.77 |
| P/OCF Ratio | 1.75 |
| PEG Ratio | n/a |
Evratios
| Measure | Value |
|---|
| EV / Earnings | 1.80 |
| EV / Sales | 0.72 |
| EV / EBITDA | 1.27 |
| EV / EBIT | 1.47 |
| EV / FCF | 1.34 |
Financialposition
| Measure | Value |
|---|
| Current Ratio | 2.56 |
| Quick Ratio | 2.23 |
| Debt / Equity | 0.32 |
| Debt / EBITDA | 0.56 |
| Debt / FCF | 0.59 |
| Interest Coverage | 81.68 |
Financialefficiency
| Measure | Value |
|---|
| Return on Equity (ROE) | 54.93% |
| Return on Assets (ROA) | 24.56% |
| Return on Invested Capital (ROIC) | 55.18% |
| Return on Capital Employed (ROCE) | 31.71% |
| Weighted Average Cost of Capital (WACC) | 9.43% |
| Revenue Per Employee | $2.42M |
| Profits Per Employee | $973,901 |
| Employee Count | 191 |
| Asset Turnover | 0.80 |
| Inventory Turnover | 1.88 |
Taxes
| Measure | Value |
|---|
| Income Tax | 16.23M |
| Effective Tax Rate | 7.98% |
Stockprice
| Measure | Value |
|---|
| Beta (5Y) | 1.41 |
| 52-Week Price Change | -49.65% |
| 50-Day Moving Average | 7.80 |
| 200-Day Moving Average | 7.67 |
| Relative Strength Index (RSI) | 25.27 |
| Average Volume (20 Days) | 1,472,548 |
Shortselling
| Measure | Value |
|---|
| Short Interest | 14.67M |
| Short Previous Month | 15.42M |
| Short % of Shares Out | 18.82% |
| Short % of Float | 22.26% |
| Short Ratio (days to cover) | 14.92 |
Incomestatement
| Measure | Value |
|---|
| Revenue | 462.25M |
| Gross Profit | 417.01M |
| Operating Income | 227.24M |
| Pretax Income | 203.40M |
| Net Income | 186.02M |
| EBITDA | 262.55M |
| EBIT | 227.24M |
| Earnings Per Share (EPS) | $2.08 |
Balancesheet
| Measure | Value |
|---|
| Cash & Cash Equivalents | 256.69M |
| Total Debt | 147.46M |
| Net Cash | 109.24M |
| Net Cash Per Share | $1.40 |
| Equity (Book Value) | 460.83M |
| Book Value Per Share | 5.93 |
| Working Capital | 293.16M |
Cashflow
| Measure | Value |
|---|
| Operating Cash Flow | 253.94M |
| Capital Expenditures | -3.52M |
| Depreciation & Amortization | 35.31M |
| Net Borrowing | 149.50M |
| Free Cash Flow | 250.42M |
| FCF Per Share | $3.21 |
Margins
| Measure | Value |
|---|
| Gross Margin | 90.21% |
| Operating Margin | 49.16% |
| Pretax Margin | 44.00% |
| Profit Margin | 40.49% |
| EBITDA Margin | 56.80% |
| EBIT Margin | 49.16% |
| FCF Margin | 54.17% |
Dividends
| Measure | Value |
|---|
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -40.04% |
| Shareholder Yield | -40.04% |
| Earnings Yield | 36.58% |
| FCF Yield | 56.41% |
Analystforecasts
| Measure | Value |
|---|
| Price Target | $15.33 |
| Price Target Difference | 169.18% |
| Analyst Consensus | Buy |
| Analyst Count | 6 |
| Revenue Growth Forecast (3Y) | 3.47% |
| EPS Growth Forecast (3Y) | -8.02% |
Stocksplits
| Measure | Value |
|---|
| Last Split Date | Mar 26, 2019 |
| Split Type | Reverse |
| Split Ratio | 1:5 |
Scores
| Measure | Value |
|---|
| Altman Z-Score | 2.57 |
| Piotroski F-Score | 5 |
Fairvalue
| Measure | Value |
|---|
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | |
| Graham Upside | |